Small Cap Feast

26th April 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:

No joiners today.

Biodexa Pharmaceuticals Plc has left AIM.

What’s Cooking In The IPO Kitchen?

Golden Metal Resources Plc a mineral exploration company focused on tungsten, gold, copper, silver and zinc within Nevada, USA intends to join AIM. It was established on 22 April 2021 as a company registered in England and Wales for the purpose of holding all of the Nevada mining assets of Power Metal Resources plc (AIM:POW). The Company holds four mining assets comprising the wholly owned Pilot Mountain, Garfield and Stonewall projects together with an earn-in option over the Golconda Summit project. Each of the projects consists of mining claims located entirely on land managed by the United States Bureau of Land Management. Expected Admission Early May 2023.

Ashoka WhiteOak Emerging Markets Trust Plc intends to join the Premium Segment of the London Stock Exchange. The Company is a new UK investment trust seeking to achieve long-term capital appreciation through investment primarily in quoted securities that provide exposure to global Emerging Markets and intends to raise £100m at 100p per ordinary share. Expected Admission 3 May 2023.

M7 Box+ REIT plc, a newly established, externally managed closed-ended investment company announces that it intends to join the Wholesale segment of IPSX. Upon Admission, the Company proposes to acquire a portfolio of seven let and operational e-warehouses from M7 Box+ II LP. As at 31 December 2022, the Property Portfolio was valued at £228.9m. Expected Admission April 2023

Breakfast Buffet

Biome Technologies 123.0p £4.6m (BIOM.L)
The technology group with two divisions (Bioplastics and Radio Frequency) announces its results for the year ended 31 December 2022. Group revenues increased by 7.9% to £6.2m, consisting of £4.4m from Bioplastics and £1.8m from Radio Frequency. Bioplastics revenues declined 8.4%, due to a significant reduction in demand from a long established customer for filmic material. Radio Frequency revenue increased by 91.6% as the division continues to diversify its application base. Group LBITDA of £0.4m (2021: LBITDA of £0.6m) was better than market expectations. Cash position was £0.8m (2021: £1.0m) with no bank borrowings. Revenues for the quarter ended 31 March 2023 was £1.9m, 77% ahead of the same period last year (2022 Q1: £1.1m) and in line with management's expectations.

Challenger Energy Group 0.11p £10.2m (CEG.L)
The Caribbean and Americas focused oil and gas company, with a range of oil production, development, appraisal, and exploration assets, provides the highlights from its technical assessment of the AREA OFF-1 block, offshore Uruguay. Initial prospect inventory of 1-2bn barrels has been defined from CEG's 2D seismic reprocessing work, three sizeable prospects have thus far been identified and prospects are seismically-derived including: 1) Teru Teru prospect 460 km2 in areal extent, in excess of 700 MMboe, 2) Anapero prospect 500 km2 in areal extent; an estimated ultimate recoverable resource in excess of 500MMboe; and 3) Lenteja prospect 425 km2 in areal extent; an estimated ultimate recoverable resource c. 500MMboe. Next steps is to farm-out to industry partners to fast track 3D seismic acquisition.

Image Scan Holdings 2.3p £3.1m (IGE.L)
The specialist in X-ray imaging for the security and industrial inspection markets, announces its interim results for the six months ended 31 March 2023. Order intake increased by 81% to £1,858k (H1 2022: £1,029k),; revenue increased by 85% to £1,459k (H1 2022: £790k); profit before tax was £16k (H1 2022: loss of £345k), and the Company held bank balance of £1,003k (H1 2022: £777k). The Company delivered a large volume portable X-ray systems to a Spanish security customer and the Company aim to deliver full year results in line with market expectations.

Kibo Energy* 0.07p £2.1m (KIBO.L)
The renewable energy-focused development company announces that further to its RNS announcement on 11 April 2023, the Company has received notices to exercise 284,524,625 Kibo warrants for which 284,524,625 ordinary Kibo shares at a price of £0.001 will be issued to the Institutional Investor RiverFort Global Opportunities PCC Ltd. Among the proceeds of c.£284k, £68k is retained by the Institutional Investor as a reduction against the outstanding loan facility. Kibo has also awarded 1,262,300,283 warrants to the Institutional Investor under the agreed reprofiling terms of the facility. In addition, conversion notices have been received for the 7% Convertible Loan Note Instrument dated 7 January 2022. The amount outstanding (including accrued interest) of £714,517 has been converted at a deemed price of 0.14p, resulting in the issue of 510,369,286 new shares. The noteholders include certain directors and senior management.

Physiomics* 3p £2.9m (PYC.L)
The leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, announces the signature of a Collaborative Services Agreement with ValiRx's wholly owned subsidiary Inaphaea BioLabs Limited. The agreement recognises the synergy between Inaphaea's growing capabilities as a translational contract research organisation (tCRO®) providing in-vitro laboratory-based services and Physiomics' in-silico capabilities for advanced statistical analyses, machine learning techniques, data handling and visualisation, as well as biological modelling. Under the agreement, service users of Inaphaea will be able to benefit from Physiomics capabilities in a single service contract with Inaphaea.

Polarean Imaging 24.25p £51.71m (POLX.L)
The medical imaging technology company announces that it has received its first order for a gas blend cylinder for the production of XENOVIEW from Cincinnati Children's Hospital Medical Centre (Cincinnati Children's). XENOVIEW is the only hyperpolarised contrast agent approved by the U.S. FDA for use with magnetic resonance imaging and evaluation of lung ventilation in adults and paediatric patients aged 12 years and older. The cylinder should provide adequate doses for over 100 patient scans. Cincinnati Children's has conducted the pioneering research in adolescent children and expects to begin scanning of hospital clinic patients in May.

Sanderson Design Group 139p £99.3m (SDG.L)
The luxury interior design and furnishings group announces its audited results for the year ended 31 January 2023. Revenue was unchanged at £112.0m (FY2022: £112.2m), including licensing revenue up 25.0% at £6.5m (FY2022: £5.2m). Adjusted underlying profit before tax was £12.6m (FY2022: £12.5m). The Group held cash of £15.4m (FY2022: £19.1m). Significant licence renewals include Bedeck, NEXT and Williams Sonoma along with strong generation of new collaborations including Disney and performance from Japanese partnerships. The Board's expectations for the year remain unchanged.

Skillcast Group 21.5p £19.2m (SKL.L)
The provider of content and technology for digital compliance transformation, announces its audited results for the year ended 31 December 2022. Revenue increased 17% to £9.8m (2021: £8.4m), with ARR up by 16% to £6.8m. Adjusted LBITDA was £0.3m (2021: EBITDA of £1.1m) and the Company held cash of £7.7m (2021: £7.9m). Recurring subscriptions contributed to 68% of total revenues (2021: 62%) and total client numbers grew to over 1,000. Trading since the period end has continued to increase on the prior year and remains consistent with market expectations.

Warpaint London 210p £161.2m (W7L.L)
The specialist supplier of colour cosmetics and owner of the W7 and Technic brands, announces its audited results for the year ended 31 December 2022. Group revenue increased by 28% to £64.1m (2021: £50.0m), gross profit margin increased to 36.4% (2021: 33.8%) and EBITDA increased 56% to £11.7m (2021: £7.5m). The Group held cash of £5.9m with no debt. USA sales grew by 55% in US dollar terms and the Group are confident to deliver profitable future growth.

Zinc Media Group 88.5p £19.3m (ZIN.L)
The award-winning television, brand and audio production group, announces its audited results for the year ended 31 December 2022. Revenue increased 72% to £30.1m (FY21: £17.5m). Adjusted EBITDA was £0.1m, compared to a loss of £0.6m in FY21 and loss before tax was £3.3m (FY21: £2.6m). The Company held cash 0f £3.6m. The successful acquisition of The Edge in August 2022 has brought a quality, high margin business with significant repeat revenue. Group's pipeline remains strong with a further £6m of revenue and the Group is trading ahead of market expectations.

26 April 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram